Prevalência de Síndrome Metabólica em uma população de pacientes com excesso de peso (funcionários de um hospital de referência)

Objective: To evaluate the prevalence of metabolic syndrome (MS) in a population of overweight patients. Methods: A cross-sectional study was conducted in 290 patients, regularly receiving care at the internal medicine ambulatory of the Division of Occupational Medicine at Hospital de Clínicas de Porto Alegre, who had complaints of overweight. Inclusion criteria were age over 18 years, body mass index equal or higher than 25 kg/m2 and absence of diabetes mellitus. MS was defined according to criteria by the National Cholesterol Education Program Adult Treatment Panel III. Results: Prevalence of MS in this group of individuals was 20.0%. When only patients with obesity were assessed, prevalence was 24.6%. Conclusions: Prevalence of MS was similar to that of the general population, even in the group of obese patients, a group that theoretically has higher risk of developing MS.Objetivo: Avaliar a prevalência da síndrome metabólica (SM) em uma população de pacientes com excesso de peso. Métodos: Estudo transversal realizado com 290 pacientes atendidos no ambulatório de medicina interna do Serviço de Medicina Ocupacional do Hospital de Clínicas de Porto Alegre, que consultaram por queixa de excesso de peso. Os critérios de inclusão foram idade acima de 18 anos, índice de massa corporal igual ou superior a 25 kg/m2 e ausência de diabetes melito. A SM foi definida segundo os critérios do National Cholesterol Education Program Adult Treatment Panel III. Resultados: A prevalência geral da SM neste grupo de indivíduos foi de 20,0%. Quando avaliamos apenas os pacientes com obesidade, a prevalência foi de 24,6%. Conclusões: A prevalência da SM foi semelhante à da população em geral, mesmo no grupo de obesos – um grupo teoricamente com maior risco de desenvolvimento da síndrome

Heart failure secondary to myocarditis after SARS-CoV-2 reinfection : a case report

Introduction: Cardiac involvement in COVID-19 can range from mild damage to severe myocarditis. The precise mechanism by which COVID-19 causes myocardial injury is still unknown. Myocarditis following administration of COVID-19 vaccines, especially those based on mRNA, has also been described. How- ever, no reports of heart failure following reinfection with SARS-CoV-2 in patients immunized with an inactivated vaccine have been identified. Case description: The patient was a 47-year-old male construction worker of African descent, with type II diabetes and a history of infection by SARS-CoV-2 in December 2020 and May 2021, confirmed by RT-PCR. He received two doses of an inactivated vaccine against COVID-19. Between the two COVID-19 episodes with positive RT-PCR, he had two episodes of bacterial lung infection. After the second episode of SARS-CoV-2 infection, he was diagnosed with severe heart failure as a sequela of myocarditis. Conclusion: It is essential to perform a thorough follow-up after infection with SARS-CoV-2 since, even with proper immunization, it is possible that the patient was reinfected and suffered severe cardiac se- quelae as a consequence. The hypothesis of an etiology associated with the use of an inactivated vaccine against COVID-19, with a potential immune enhancement mechanism following reinfection with SARS-CoV-2, cannot be rejected